Mechanism of Action

Tesamorelin mimics the action of an endogenous hormone in the body known as growth hormone-releasing hormone (GHRH). It binds with the growth hormone-releasing hormone receptors (GHRHr) located in the anterior pituitary gland. This triggers the release of growth hormone (GH) which binds with various cells like myocytes, hepatocytes, adipocytes, and osteoblasts.

Class of Compound

Peptide

Street Names

Tesamorelin Acetate, Egrifta, LGW5H38VE3, TH9507, UNII-LGW5H38VE3

Effects

• Manages HIV associated lipodystrophy by cutting down VAT
• Triggers the production of IGF-1
• Initiates lipolysis

Side Effects and Dangers

• Redness/itching at the site of administration
• Increased urination
• Chest pain

Top Studies

• Effects of Tesamorelin on Inflammatory Markers in HIV Patients with Excess Abdominal Fat: Relationship with Visceral Adipose Reduction
• Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy